SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000886163-23-000089
Filing Date
2023-11-13
Accepted
2023-11-09 21:48:31
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A lgnd-20231109.htm   iXBRL 8-K/A 28877
2 EX-99.1 q32023earningsrelease_ex99.htm EX-99.1 221247
6 image1a.jpg GRAPHIC 36525
  Complete submission text file 0000886163-23-000089.txt   451577

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20231109.xsd EX-101.SCH 1911
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20231109_lab.xml EX-101.LAB 24134
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20231109_pre.xml EX-101.PRE 12518
8 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20231109_htm.xml XML 2744
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-33093 | Film No.: 231394434
SIC: 2834 Pharmaceutical Preparations